An eight-month clinical study of LA-2575 30.0 mg: a new 4-month, subcutaneous delivery system for leuprolide acetate in the treatment of prostate cancer

By Sartor O.   Dineen M.K.   Perez-Marreno R.   Chu F.M.   Carron G.J.   Tyler R.C.  

Urology, Vol. 62, Iss. 2, 2003-08 ,pp. : 319-323

Elsevier

Access to resources Recommend Favorite

Leuprolide acetate (30-mg depot every four months) in the treatment of advanced prostate cancer

By Sharifi R.   Knoll L.D.   Smith J.   Kramolowsky E.  

Urology, Vol. 51, Iss. 2, 1998-02 ,pp. : 271-276

Elsevier

Access to resources Recommend Favorite

Cross-Study Review of the Clinical Efficacy of Apomorphine SL 2 and 3 mg: - Pooled Data from Three Placebo-Controlled, Fixed-Dose Crossover Studies

By Stief C.   Padley R.J.   Perdok R.J.   Sleep D.J.  

European Urology Supplements, Vol. 1, Iss. 3, 2002-05 ,pp. : 12-20

Elsevier

Access to resources Recommend Favorite

Bilateral supernumerary kidneys: Incidental finding in a three-month-old infant

By Yisau Abdulkadir  

African Journal of Urology, Vol. 16, Iss. 2, 2010-06 ,pp. : 46-48

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and Tolerability of Intravenous Paricalcitol in Calcitriol-Resistant Hemodialysis Patients with Secondary Hyperparathyroidism: 12-Month Prospective Study

By Tonbul Halil Zeki   Solak Yalcin   Atalay Huseyin   Turkmen Kultigin   Altintepe Lutfullah  

Renal Failure, Vol. 34, Iss. 3, 2012-04 ,pp. : 297-303

Informa Healthcare

Access to resources Recommend Favorite